Lymphocyte Viral Vector for HIV Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HIV, including combination antiretroviral therapy, have limitations such as drug toxicities and the emergence of drug-resistant viruses, and immunotherapy approaches have shown limited success in achieving a functional cure.
Innovation Solution
Development of a viral vector system comprising a therapeutic cargo portion with a nucleotide sequence encoding a soluble exogenous factor, such as anti-HIV antibodies or soluble CD4 proteins, regulated by a T cell-responsive promoter, and a lentiviral particle capable of infecting lymphocytes to enhance HIV-specific cellular immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If combination antiretroviral therapy (cART) is used to limit HIV-1 replication, then viral replication is controlled and disease progression is retarded, but drug toxicities and emergence of drug-resistant viruses occur
Solution Approach 1:
The patent introduces an intermediary mechanism - a viral vector system that delivers genes encoding HIV-inhibiting factors (such as antibodies or soluble CD4) to lymphocytes. These modified lymphocytes then serve as living factories that produce and secrete anti-HIV factors in vivo, mediating viral inhibition without requiring continuous exposure to toxic antiretroviral drugs. This intermediary genetic therapy approach bypasses the direct harmful effects of cART while achieving similar or superior viral control.
Solution Approach 2:
The invention enables the patient's own lymphocytes to serve themselves by equipping them with genetic instructions to autonomously produce HIV-inhibiting factors. Once the lymphocytes are transduced with the therapeutic gene, they continuously express and secrete anti-HIV proteins without external intervention, creating a self-sustaining therapeutic system that eliminates the need for ongoing drug administration and avoids drug-induced toxicity and resistance.
2Duration of action of moving object
If traditional anti-retroviral therapy is used to delay AIDS or death, then disease progression is slowed, but a functional cure is not achieved
Solution Approach 1:
The patent applies preliminary action by modifying the patient's lymphocytes ex vivo before reinfusion. The lymphocytes are pre-equipped with genetic instructions to produce HIV-inhibiting factors, and this genetic modification is established before the cells are returned to the patient. This preliminary genetic endowment ensures that the lymphocytes will autonomously produce therapeutic factors in vivo, creating a lasting functional cure mechanism rather than relying on continuous external drug intervention.
3Reliability
If immunotherapy approaches are used to enhance HIV-specific cellular immune responses, then immune function is augmented, but success has been limited
Solution Approach 1:
The invention fundamentally changes the parameter of immune response production from transient activation to sustained endogenous synthesis. Instead of temporarily stimulating immune cells with vaccines or cytokines (which has limited success), the patent permanently alters the functional parameter of lymphocytes by introducing genetic instructions for continuous production of HIV-inhibiting factors. This parameter change from transient to permanent expression achieves more reliable and productive clinical outcomes.
Data Source
AI summary
The present disclosure relates generally to immunization and immunotherapy for the treatment or inhibition of HIV. In embodiments, a viral vectors are disclosed that comprise therapeutic cargo portions comprising a nucleotide sequence that encodes at least one soluble exogenous factor capable of inhibiting HIV infection, and a T cell-responsive promoter that regulates expression of the nucleotide sequence.